deltatrials
Completed PHASE4 NCT00150514

Effects of Sublingual Immunotherapy on Grasspollen Allergy

A Placebo Controlled, Double-Blind, Randomised Study to Assess Efficacy of Sublingual Immunotherapy in Patients With Grass Pollen Allergy Through Assessment of Its Immunological Effects on the Mucosal Tissue of the Nose.

Sponsor: Radboud University Medical Center

Conditions Hayfever
Updated 5 times since 2017 Last updated: Sep 7, 2005 Started: Jan 31, 2002 Completion: Dec 31, 2006

A PHASE4 clinical study on Hayfever, this trial is completed. The trial is conducted by Radboud University Medical Center and has accumulated 5 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jan 2021 · 48 months · monthly snapshotCompleted~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshotCompleted~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted

Change History

5 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE4

  4. Jan 2021 — Mar 2022 [monthly]

    Completed PHASE4

  5. Jan 2017 — Jan 2021 [monthly]

    Completed PHASE4

    First recorded

Jan 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Radboud University Medical Center
Data source: Radboud University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations